Patent Asset definition

Patent Asset means a patent application filed in any jurisdiction, together with any patent application claiming priority thereto (including but not limited to continuation, divisional, substitution, or national phase and validation applications claiming priority thereto; provided that, in the case of a continuation-in-part patent application, only with respect to a patent issued thereon and only to the extent that the claims in that issued patent are supported in the application(s) to which priority is claimed), and patents issuing on said patent application or patent applications claiming priority thereto (where issued patents include without limitation registrations, reissues, reexaminations and extensions).
View Source
Patent Asset a magnetic filter and rotary joint device, with an appraisal value of approximately RMB7,100,000 “Patent Exclusive License Agreement” the patent exclusive license agreement entered into between the Licensor and the Licensee on June 23, 2022
View Source
Patent Asset means a patent application filed in any jurisdiction, together with any patent application claiming priority thereto (including but not limited to continuation, divisional, substitution, or national phase and validation applications claiming priority thereto, but in the case of a continuation-in-part application only to the extent that all claims in a patent issued on the continuation-in-part application are supported in the application(s) to which priority is claimed) and together with patents issuing on said patent application or said patent application claiming priority thereto (where issued patents include without limitation registrations, reissues, reexaminations and extensions).
View Source

Examples of Patent Asset in a sentence

  • Thereafter, ACORDA’s royalty obligations related to that Patent Asset shall terminate and such patent or patent application shall no longer be deemed a Patent Asset.

  • DSS’ obligations to provide indemnification under this clause shall be full-recourse obligations with respect to DSS, and is not limited to the value of the Patent Asset Proceeds.

  • If CPEC elects to file, prosecute or maintain such patent application or patent then, at CPEC’s option, either (a) such patent or patent application in such country shall no longer be deemed a Patent Asset under this Agreement or (b) ARCA shall reimburse CPEC for all fees, costs and expenses incurred by CPEC in filing, prosecuting or maintaining such patent application or patent upon invoice therefor.

  • Thereafter, INDEVUS' royalty obligations related to that Patent Asset in such country shall terminate and such patent or patent application in such country shall no longer be deemed a Patent Asset.

  • Thereafter, INDEVUS’ royalty obligations related to that AVENTIS Patent Asset in such country shall terminate and such patent or patent application in such country shall no longer be deemed an AVENTIS Patent Asset.

  • This Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section 8.2 and 8.3 below, the term of this Agreement shall continue in effect on a country-by-country basis until the expiration of the last to expire Patent Asset in such country..

  • This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to the conflicts of law principles thereof except matters of patent law, which shall be determined in accordance with the national intellectual property laws relevant to the Patent Asset in question.

  • Isis shall promptly give notice to Merck of the grant, lapse, revocation, surrender, invalidation or abandonment of any Isis Research Patent Asset or Isis Patent Asset licensed or sub-licensed to Merck by Isis for which Isis is responsible and Merck shall give such notice to Isis for Isis Research Patent Assets for which Merck is responsible.

  • Thereafter, INDEVUS’ royalty obligations related to that ▇▇▇▇▇▇▇▇ Patent Asset in such country shall terminate and such patent or patent application in such country shall no longer be deemed a ▇▇▇▇▇▇▇▇ Patent Asset.

  • In each case in which Seller or any of its Subsidiaries has acquired ownership (or claimed or purported to acquire ownership) of any Patent Assets from any Person (including any employee, officer, director, consultant and contractor of Seller or any Subsidiary), Seller or its applicable Subsidiary has obtained an assignment sufficient to transfer ownership of and all rights with respect to such Patent Asset to Seller or such Subsidiary.